Nautilus Biotechnology Reports $0.2 Million Revenue and $15.6 Million Net Loss

What happened

Nautilus Biotechnology reported third-quarter 2026 revenue of $234,000, made up of grant and service revenue, and a net loss of $15.6 million. Operating expenses were $16.9 million, and cash, cash equivalents and investments totaled $114.3 million at September 30, 2026.

Confirmed

Global impact / market context

The company spends far more than it earns, so it depends on its $114.3 million of cash to fund operations. That cash covers current costs for now, but continued losses would eventually force it to raise more money, possibly by selling shares, which can reduce existing owners' stakes.

Analyst inference

Nautilus is a development-stage life-science tools company, not yet a steady product seller. Investors will likely judge it on assay and Voyager platform progress against its cash burn, because revenue is small and grants, not product sales, made up most of the quarter's reported revenue.

Analyst inference

What to watch

1. The company plans 20 proteoform assays through mid-2028, so watch how many it actually releases and whether assay performance data hold up in later testing. Confirmed
2. Watch whether Nautilus gives a specific launch timeline or sales plan for its Voyager platform, since a clear commercial path would help investors judge when product revenue might grow. Proposed
3. Track the quarterly cash balance against operating expenses; a shrinking cash pile without new funding could push the company toward selling shares or cutting spending. Analyst inference

Evidence

• Original source link unavailable